Three years ago Dave Johnson steered Acerta to a $7 billion buyout deal with AstraZeneca, setting up a relatively quickly transition of acalabrutinib into the oncology market, where it’s now sold as Calquence.
Now, Johnson is back at the helm of a new biotech startup, and he’s still interested in doing something new in the sizzling cancer R&D field — this time focusing on antibody-drug conjugates. Johnson has a $58 million A round to get started.
Word arrived Monday morning that Johnson is at the helm of a company called VelosBio, which is pursuing antibody-drug conjugates.
Arix Bioscience — which snagged an 11.2% interest for $11 million — and Sofinnova Ventures led the round. Pappas Ventures and Chiesi Ventures joined existing investors Takeda Ventures and Decheng Capital.
The CMO is Langdon Miller, who worked at a slate of biotechs, including a 2-year stint at Gilead, where he was VP of clinical research for oncology.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,300+ biopharma pros who read Endpoints News by email every day.Free Subscription